Juvenile Hemochromatosis: Rheumatic Manifestations of 2 Sisters Responding to Deferasirox Treatment. A Case Series and Literature Review

References

• Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Gen. 1996;13:339–408.
   Web of Science ®Google Scholar
• Santacoloma M, Londoño HG, Limas LM. Hereditary hemochromatosis: presentation of 2 cases and literature review. Rev Col Gastroenterol. 2010;25(2):188–193.
   Google Scholar
• Pietrangelo A. Juvenile hemochromatosis. J Hepatol. 2006;45(6):892–894. doi:10.1016/j.jhep.2006.09.003
   Google Scholar
• Lok CY, Merryweather-Clarke AT, Viprakasit V, et al. Iron overload in the Asian community. Blood. 2009;114(1):20–25. doi:10.1182/blood-2009-01-199109
   Web of Science ®Google Scholar
• McDonald CJ, Wallace DF, Crawford DH, Subramaniam VN. Iron storage disease in Asia‐Pacific populations: the importance of non‐HFE mutations. J Gastroenterol Hepatol. 2013;28(7):1087–1094.
   Web of Science ®Google Scholar
• Schumacher HR Jr. Hemochromatosis and arthritis. Arthritis Rheum. 1964;7:41–50. doi:10.1002/art.1780070106
   PubMed Web of Science ®Google Scholar
• Carroll GJ, Breidahl WH, Olynyk JK. Characteristics of the arthropathy described in hereditary hemochromatosis. Arthritis Care Res (Hoboken). 2011;64(1):9–14.
   Web of Science ®Google Scholar
• Vaiopoulos G, Papanikolaou G, Politou M, Jibreel I, Sakellaropoulos N, Loukopoulos D. Arthropathy in juvenile hemochromatosis. Arthritis Rheum. 2003;48(1):227–230.
   Web of Science ®Google Scholar
• Gottschalk R, Neeck G, Wigand R, Vogtherr B, Kaltwasser JP. Hemochromatosis arthropathy–an early manifestation of genetic hemochromatosis. Z Rheumatol. 1997;56(3):156–162.
   Web of Science ®Google Scholar
• Nguyen CD, Morel V, Pierache A, et al. Bone and joint complications in patients with hereditary hemochromatosis: a cross-sectional study of 93 patients. Ther Adv Musculoskelet Dis. 2020;12:1759720X20939405. doi:10.1177/1759720X20939405
   Web of Science ®Google Scholar
• Wimalawansa SM, Alsamkari R. Unusual presentation of hemochromatosis as isolated metacarpophalangeal joint osteoarthritis: A case report. Hand (N Y). 2011;6:329–332. doi:10.1007/s11552-011-9335-7
   Google Scholar
• Sahinbegovic E, Dallos T, Aigner E, et al. Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum. 2010. 62:3792–3798.
   PubMed Web of Science ®Google Scholar
• McDonnell SM, Preston BL, Jewell SA, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med. 1999;106:619–624. doi:10.1016/S0002-9343(99)00120-5
   PubMed Web of Science ®Google Scholar
• Guggenbuhl P, Brissot P, Loréal O. Haemochromatosis: the bone and the joint. Best Pract Res Clin Rheumatol. 2011;25(5):649–664. doi:10.1016/j.berh.2011.10.014
   PubMed Web of Science ®Google Scholar
• Husar-Memmer E, Stadlmayr A, Datz C, Zwerina J. HFE-related hemochromatosis: an update for the rheumatologist. Curr Rheumatol Rep. 2014;16(1):393. doi:10.1007/s11926-013-0393-4
   Web of Science ®Google Scholar
• Oke AR, Wong E, McCrae F, Young-Min S. Hereditary hemochromatosis arthropathy and Doppler ultrasound findings of synovitis. Rheumatology. 2017;56(7):1240–1241. doi:10.1093/rheumatology/kex069
   Web of Science ®Google Scholar
• Parperis K. Comment on: hereditary hemochromatosis arthropathy and Doppler ultrasound findings of synovitis. Rheumatology. 2018;57(4):765–766. doi:10.1093/rheumatology/kex436
   Web of Science ®Google Scholar
• Schumacher HR. Articular cartilage in the degenerative arthropathy of hemochromatosis. Arthritis Rheum. 1982;25:1460–1468. doi:10.1002/art.1780251212
   Web of Science ®Google Scholar
• Guggenbuhl P, Deugnier Y, Boisdet JF, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int. 2005;16(12):1809–1814. doi:10.1007/s00198-005-1934-0
   PubMed Web of Science ®Google Scholar
• Valenti L, Varenna M, Fracanzani AL, et al. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. 2009;20:549–555. doi:10.1007/s00198-008-0701-4
   Web of Science ®Google Scholar
• Angelopoulos NG, Goula AK, Papanikolaou G, Tolis G. Osteoporosis in HFE2 juvenile hemochromatosis. A case report and review of the literature. Osteoporosis Int. 2006;17(1):150–155. doi:10.1007/s00198-005-1920-6
   Web of Science ®Google Scholar
• Anonymous. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3–22. doi:10.1016/j.jhep.2010.03.001
   Web of Science ®Google Scholar
• Weinberg ED. Iron loading: a risk factor for osteoporosis. Biometals. 2006;19(6):633–635. doi:10.1007/s10534-006-9000-8
   PubMed Web of Science ®Google Scholar
• Guggenbuhl P, Filmon R, Mabilleau G, Basle MF, Chappard D. Iron inhibits hydroxyapatite crystal growth in vitro. Metabolism. 2008;57:903–910. doi:10.1016/j.metabol.2008.02.004
   Web of Science ®Google Scholar
• Allen KJ, Gurrin LCP, Constantine CCP, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358:221–230. doi:10.1056/NEJMoa073286
   PubMed Web of Science ®Google Scholar
• Adams P, Brissot P, Powell LWEASL. International consensus conference on haemochromatosis. J Hepatol. 2000;33:487–496. doi:10.1016/S0168-8278(01)80874-6
   Web of Science ®Google Scholar
• Powell LW, Dixon JL, Ramm GA, Purdie DM. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166:294–301. doi:10.1001/archinte.166.3.294
   PubMedGoogle Scholar
• Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md). 2011;54(1):328. doi:10.1002/hep.24330
   Web of Science ®Google Scholar
• Schumacher HR Jr. Arthropathy in hemochromatosis. Hosp Pract (Minneap). 1998;33:81–90,93. doi:10.1080/21548331.1998.11443654
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr. Haemochromatosis. Baillieres Best Pract Res Clin Rheumatol. 2000;14:277–284. doi:10.1053/berh.2000.0065
   Web of Science ®Google Scholar
• Carroll G, Breidahl W, Olynyk J. Characteristics of the arthropathy described in hereditary hemochromatosis. Arthritis Care Res (Hoboken). 2011. 64:9–14.
   Web of Science ®Google Scholar
• Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357–362. doi:10.1016/S0140-6736(04)15436-6
   PubMed Web of Science ®Google Scholar
• Hernando D, Levin YS, Sirlin CB, Reeder SB. Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Resonance Imaging. 2014;40(5):1003–1021. doi:10.1002/jmri.24584
   PubMed Web of Science ®Google Scholar
• Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:328–343.
   PubMed Web of Science ®Google Scholar
• Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology. 1991;101(2):368. doi:10.1016/0016-5085(91)90013-B
   PubMed Web of Science ®Google Scholar
• Niederau C, Fischer R, Purschel A, Stremmel W. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107–1119. doi:10.1053/gast.1996.v110.pm8613000
   PubMed Web of Science ®Google Scholar
• Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016;388(10045):706–716.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. Journal of hepatology. 2010;53(1):3–22.
   Google Scholar
• Brissot P, De Bels F. Prise en charge de l'hémochromatose liée au gène HFE. La Presse Médicale. 2007;36(9):1295–300.
   Google Scholar
• Swinkels DW, Jorna AT, Raymakers RA. Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis.
   Google Scholar
• Tanaka C. Clinical pharmacology of deferasirox. Clin Pharmacokinet. 2014;53:679–694. doi:10.1007/s40262-014-0151-4
   Web of Science ®Google Scholar
• Cançado R, Melo MR, de Moraes Bastos R, et al. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study. Eur J Haematol. 2015;95(6):545–550. doi:10.1111/ejh.12530
   Web of Science ®Google Scholar
• Phatak P, Brissot P, Wurster M, et al. A Phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology. 2010;52(5):1671–1779. doi:10.1002/hep.23879
   Web of Science ®Google Scholar
• Nagler M, Gregor M, Wuillemin WA. Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia. Acta Haematol. 2011;126:119–121. doi:10.1159/000328039
   Web of Science ®Google Scholar